---
title: "These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295423642.md"
description: "ANI Pharmaceuticals reported strong Q2 earnings, beating estimates with $2.21 EPS and $266M sales, while affirming FY2026 guidance. Despite positive results, shares fell 3.2%. Analysts slashed price targets: Canaccord Genuity lowered its target to $90 (Hold), and Guggenheim cut its target to $119 (Buy)."
datetime: "2026-08-10T14:39:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295423642.md)
  - [en](https://longbridge.com/en/news/295423642.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295423642.md)
generator: "portal-rs"
---

# These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

**ANI Pharmaceuticals Inc** (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.

The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.

ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion.

“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI. “Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel’s sizable multi-year growth opportunity.”

ANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.

These analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.

-   Canaccord Genuity analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90.
-   Guggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.

**Considering buying ANIP stock? Here’s what analysts think:**

*Photo via Shutterstock*

### Related Stocks

- [ANIP.US](https://longbridge.com/en/quote/ANIP.US.md)

## Related News & Research

- [ANI Pharma SVP, CFO Stephen P. Carey sells 2,850 shares for $207,480](https://longbridge.com/en/news/297704077.md)
- [ANI Pharmaceuticals director Henry O. Gosebruch files initial beneficial ownership statement (Form 3)](https://longbridge.com/en/news/297228878.md)
- [ANI Pharmaceuticals to Present at September Investor Conferences | ANIP Stock News](https://longbridge.com/en/news/297901805.md)
- [ANI Pharma CEO Nikhil Lalwani disposes of 5,400 common shares worth $401,220](https://longbridge.com/en/news/297093829.md)
- [Jupiter Topco LLC Invests $3.45 Million in Rigel Pharmaceuticals, Inc. $RIGL](https://longbridge.com/en/news/297756537.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**